18th October 2022
Dr. Matthew Dunne, Dr. Samuel Kilcher and Dr. Anja Keller join us from the Swiss Federal Institute of Technology (ETH Zurich), with the goal of developing synthetic precision antimicrobials for medical indications across infectious and inflammatory diseases.
The new Division of Antimicrobial Vector Innovation builds on existing synthetic phage technology established at ETH and our own experience in developing and commercializing precision antimicrobials for many years.
Co-Directors Dr. Matthew Dunne and Dr. Samuel Kilcher bring with them extensive experience and knowledge within the fields of phage therapy, molecular microbiology, genetic engineering, and technology development.
If you want to learn more about the huge potential of synthetic phage technology in the quest for sustainable antimicrobial solutions, read this great article from ETH: https://www.sciencedirect.com/science/article/pii/S1879625721001607
We are very happy to have our new colleagues onboard as we continue the fight against bacterial infections and antimicrobial resistance!